The efficacy and safety of lenvatinib in the treatment of solid tumors: an up-to-date meta-analysis

Papers of special note have been highlighted as: • of interest

References

• 1. Nakamichi S, Nokihara H, Yamamoto N et al. A Phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 76(6), 1153–1161 (2015).
  Medline CASGoogle Scholar
• 2. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 141(7), 1117–1134 (2010).
  Medline CASGoogle Scholar
• 3. LENVIMA^® (lenvatinib) Capsules, for Oral use. (Accessed 15 February 2020). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206947s007lbl.pdf
  Google Scholar
• 4. Hida T, Velcheti V, Reckamp KL et al. A Phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. Lung Cancer 138, 124–130 (2019).
  MedlineGoogle Scholar
• 5. O'Day S, Gonzalez R, Kim K et al. A Phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma. J. Clin. Oncol. 31(Suppl. 15), 9026–9026 (2013).
  Google Scholar
• 6. Shoji H, Iwasa S, Kuchiba A et al. A Phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503). J. Clin. Oncol. 37(Suppl. 15), 3538–3538 (2019).
  MedlineGoogle Scholar
• 7. Capdevila J, Fazio N, Lopez CL et al. Final results of the TALENT trial (GETNE1509): a prospective multicohort Phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs). J. Clin. Oncol. 37(Suppl. 15), 4106–4106 (2019).
  Google Scholar
• 8. Kawazoe A, Fukuoka S, Nakamura Y et al. An open-label Phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706). J. Clin. Oncol. 38(Suppl. 4), 374–374 (2020).
  Google Scholar
• 9. Makker V, Rasco D, Vogelzang NJ et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, Phase 2 trial. Lancet Oncol. 20(5), 711–718 (2019). • Found the combination of an immune checkpoint inhibitor (pembrolizumab) and simultaneous inhibition of angiogenesis (lenvatinib) showed antitumor activity in patients with advanced recurrent endometrial cancer.
  Medline CASGoogle Scholar
• 10. Zhu C, Ma X, Hu Y et al. Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis. Oncotarget 7(28), 44545–44557 (2016).
  MedlineGoogle Scholar
• 11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 7(3), 177–188 (1986).
  Medline CASGoogle Scholar
• 12. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann. Intern. Med. 127(9), 820–826 (1997).
  Medline CASGoogle Scholar
• 13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 327(7414), 557–560 (2003).
  MedlineGoogle Scholar
• 14. Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet 391(10126), 1163–1173 (2018).
  Medline CASGoogle Scholar
• 15. Schlumberger M, Tahara M, Wirth LJ et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372(7), 621–630 (2015).
  Medline CASGoogle Scholar
• 16. Motzer RJ, Hutson TE, Glen H et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, Phase 2, open-label, multicentre trial. Lancet Oncol. 16(15), 1473–1482 (2015).
  Medline CASGoogle Scholar
• 17. Vergote I, Powell MA, Teneriello MG et al. Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecol. Oncol. 156(3), 575–582 (2020).
  Medline CASGoogle Scholar
• 18. Schlumberger M, Jarzab B, Cabanillas ME et al. A Phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin. Cancer Res. 22(1), 44–53 (2016).
  Medline CASGoogle Scholar
• 19. Tchekmedyian V, Sherman EJ, Dunn L et al. Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J. Clin. Oncol. 37(18), 1529–1537 (2019).
  Medline CASGoogle Scholar
• 20. Takahashi S, Kiyota N, Yamazaki T et al. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 15(7), 717–726 (2019).
  CASGoogle Scholar
• 21. Ikeda K, Kudo M, Kawazoe S et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J. Gastroenterol. 52(4), 512–519 (2017).
  Medline CASGoogle Scholar
• 22. Cabanillas ME, Schlumberger M, Jarzab B et al. A Phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer 121(16), 2749–2756 (2015).
  Medline CASGoogle Scholar
• 23. Ott PA, Hodi FS, Buchbinder EI. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front. Oncol. 5, 202 (2015).
  MedlineGoogle Scholar
• 24. Gollob JA, Wilhelm S, Carter C et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin. Oncol. 33(4), 392–406 (2006).
  Medline CASGoogle Scholar
• 25. Erman M, Benekli M, Basaran M et al. Renal cell cancer: overview of the current therapeutic landscape. Expert Rev. Anticancer Ther. 16(9), 955–968 (2016).
  Medline CASGoogle Scholar
• 26. Grünwald V, Powles T, Choueiri TK et al. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Future Oncol. 15(9), 929–941 (2019).
  CASGoogle Scholar
• 27. Guo T, Liu P, Yang J et al. Evaluation of targeted agents for advanced and unresectable hepatocellular carcinoma: a network meta-analysis. J Cancer. 10(19), 4671–4678 (2019).
  Medline CASGoogle Scholar
• 28. Wang Y, Gou Q, Xu R et al. Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study. Onco. Targets Ther. 11, 3407–3413 (2018).
  MedlineGoogle Scholar
• 29. Tian S, Quan H, Xie C et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 102(7), 1374–1380 (2011).
  Medline CASGoogle Scholar
• 30. Kaplan NM, Opie LH. Controversies in hypertension. Lancet 367(9505), 168–176 (2006).
  MedlineGoogle Scholar
• 31. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann. Intern. Med. 123, 754–762 (1995).
  Medline CASGoogle Scholar
• 32. Zhang W, Feng LJ, Teng F et al. Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials. Expert Rev. Clin. Pharmacol. 1–10 (2020). • Meta-analysis that found newly approved VEGFR-tyrosine kinase inhibitors (TKIs) significantly increase the risk of developing proteinuria events in cancer patients, especially for patients treated with lenvatinib.
  MedlineGoogle Scholar
• 33. Okamoto K, Ikemori-Kawada M, Jestel A et al. Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med. Chem. Lett. 6(1), 89–94 (2014).
  MedlineGoogle Scholar
• 34. Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat. Rev. Endocrinol. 12(4), 192–202 (2016).
  Medline CASGoogle Scholar
• 35. Qi WX, Fu S, Zhang Q et al. Bevacizumab increases the risk of infections in cancer patients: a systematic review and pooled analysis of 41 randomized controlled trials. Crit. Rev. Oncol. Hematol. 94(3), 323–336 (2015).
  MedlineGoogle Scholar
• 36. Zhang X, Ran Y, Shao Y et al. Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 81(1), 33–40 (2016).
  MedlineGoogle Scholar
• 37. Sivendran S, Liu Z, Portas LJ Jr et al. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer Treat. Rev. 38(7), 919–925 (2012). • Meta-analysis that showed the average incidence rate of fatal adverse events was 2.26% and that VEGFR-TKI treatment was associated with an increased risk of such events.
  Medline CASGoogle Scholar